Background

The efficacy and safety of upadacitinib in atopic dermatitis (AD) have been defined in clinical trials, but no real-world data are currently available. We aimed to assess the safety and effectiveness of upadacitinib in a real-world AD patient cohort that mostly included patients who failed the available systemic therapies, including dupilumab.

Methods

Prospective cohort study collecting data on upadacitinib-treated AD adult patients completing at least 16 weeks of therapy.

Results

Forty-three patients showed rapid and marked response to upadacitinib with significant reduction of all disease severity scores since the first follow-up visit. At week 16, Eczema Area and Severity Index (EASI) 75, EASI 90, and EASI 100 response was observed in 97.5%, 82.1%, and 69.2% of patients, respectively. EASI 90 response reflected the achievement of a clear or almost clear condition (POEM 0-2), self-evaluated by 79.5% of patients. Patients’ quality of life improved as suggested by the achievement of DLQI 0/1 by 38.5% of patients at week 4, and by 76.9% at week 16.

Conclusion

Elevated effectiveness and favorable safety of upadacitinib were confirmed in patients unresponsive to dupilumab, who were not included in upadacitinib trials.

中文翻译：

---

Upadacitinib 治疗中重度特应性皮炎的有效性和安全性：一项多中心、前瞻性、真实世界的队列研究

背景

upadacitinib 在特应性皮炎 (AD) 中的疗效和安全性已在临床试验中确定，但目前尚无实际数据。我们的目的是评估 upadacitinib 在真实世界 AD 患者队列中的安全性和有效性，该队列主要包括那些无法使用包括 dupilumab 在内的可用全身疗法的患者。

方法

前瞻性队列研究收集了 upadacitinib 治疗的 AD 成年患者完成至少 16 周治疗的数据。

结果

自第一次随访以来，43 名患者对 upadacitinib 表现出快速和显着的反应，所有疾病严重程度评分均显着降低。在第 16 周，湿疹面积和严重程度指数 (EASI) 75、EASI 90 和 EASI 100 分别在 97.5%、82.1% 和 69.2% 的患者中观察到。EASI 90 反应反映了明确或几乎明确的情况（POEM 0-2），79.5% 的患者自我评估。38.5% 的患者在第 4 周达到 DLQI 0/1，在第 16 周达到 76.9%，这表明患者的生活质量有所改善。

结论

在对 dupilumab 无反应的患者中证实了 upadacitinib 的有效性和良好的安全性，这些患者未包括在 upadacitinib 试验中。